Hidradenitis Suppurativa: A Chronic Skin Battle

Get a snapshot of the 7MM landscape—view the infographic now!: Click Here

Hidradenitis Suppurativa Epidemiological Segmentation
The epidemiological segmentation of Hidradenitis Suppurativa across the 7MM from 2020 to 2034 covers:

Total prevalent cases of Hidradenitis Suppurativa in the US
Total diagnosed prevalent cases in the US
Gender-specific cases in the US
Age-specific cases in the US
Stage-specific cases in the US
Treated prevalent cases in the US

Hidradenitis Suppurativa Epidemiology
In 2023, the epidemiological trends for Hidradenitis Suppurativa across the 7MM were as follows:

Approximately 6.2 million total prevalent cases of HS were recorded across the 7MM, with numbers expected to rise by 2034.
The US accounted for the highest number of diagnosed cases, with nearly 877,600 in 2023.
Within the EU4 and the UK, Germany reported the highest diagnosed cases, whereas Spain had the lowest.
HS was more prevalent in females (~75%) compared to males (~25%) in the US, EU4, and UK; in contrast, in Japan, males constituted nearly 70% of cases, with females making up about 30%.
The 30–39 age group was the most affected in the US, representing nearly 26% of diagnosed cases.
Among the Hurley stages, Stage I was the most common, with roughly 480,000 cases in the US in 2023.

You’ve seen the key stats—now discover what’s driving them: Click Here

Hidradenitis Suppurativa Market
The total market size for Hidradenitis Suppurativa in the 7MM was approximately USD 1.4 billion in 2023.

Hidradenitis Suppurativa Market Drivers

The introduction of novel therapies such as Povorcitinib (INCB054707), Izokibep, and RINVOQ (upadacitinib) is expected to offer more targeted treatment options, improving patient outcomes and driving market growth.
Increasing awareness of HS and enhanced diagnostic techniques are likely to enable earlier diagnosis and treatment, thus expanding the market for HS therapies.

Hidradenitis Suppurativa Market Barriers

The complexity in diagnosing and managing HS due to its heterogeneous presentation and progression poses challenges in developing standardized treatment protocols and conducting clinical trials.
The high cost of new therapies and limited access in certain regions may restrict the broad adoption of these treatments.

Hidradenitis Suppurativa Emerging Therapies